Literature DB >> 31292624

Diagnostic score of cardiac involvement in AL amyloidosis.

Martin Nicol1, Mathilde Baudet1, Stephanie Brun2, Stephanie Harel3, Bruno Royer3, Marguerite Vignon4, Olivier Lairez2, David Lavergne5, Arnaud Jaccard5, David Attias6, Laurent Macron6, Etienne Gayat7,8, Alain Cohen-Solal1,8, Bertrand Arnulf2,8, Damien Logeart1,8.   

Abstract

AIMS: Early diagnosis of cardiac involvement is a key issue in the management of AL amyloidosis. Our objective was to establish a diagnostic score of cardiac involvement in AL amyloidosis and to compare it with the current consensus criteria [i.e. left ventricular hypertrophy >12 mm and N-terminal pro b-type natriuretic peptide (NT-proBNP) >332 ng/L]. METHODS AND
RESULTS: We carried out a prospective and multicenter study on AL amyloidosis patients who underwent cardiac evaluation including clinical examination, electrocardiography (ECG), cardiac biomarkers, transthoracic echocardiography (TTE), and cardiac magnetic resonance imaging (CMR). Cardiac involvement was based on CMR and/or endomyocardial biopsy. In a derivation cohort of 114 patients (82 with cardiac involvement), the highest diagnostic accuracy was observed with NT-proBNP and troponin blood levels, TTE-derived global longitudinal strain (LS), and apical to basal LS gradient. By using multivariate analysis, we established a diagnostic score including global LS ≥-17% (1 point), apical/(basal + median) LS ≥0.90 (1 point), and troponin T >35 ng/L (1 point). A score >1 was associated with sensitivity of 94% and specificity of 97%, an area under the curve of 0.98 [95% confidence interval (CI) 0.93-0.99] as well as a net reclassification index of 0.39 (95% CI 0.28-0.46) when compared with consensus criteria. In a validation cohort of 73 AL amyloidosis patients, the area under the receiver operating characteristic curve of the diagnostic score was 0.97 (95% CI 0.90-0.99).
CONCLUSION: Combining T troponin blood levels and two echo-derived strain parameters leads to very high accuracy for diagnosing cardiac involvement in AL amyloid patients. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  AL amyloidosis; cardiac amyloidosis involvement; cardiac biomarkers; diagnostic score; global longitudinal strain and apical sparing

Mesh:

Substances:

Year:  2020        PMID: 31292624     DOI: 10.1093/ehjci/jez180

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  5 in total

Review 1.  Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.

Authors:  John Alan Gambril; Aaron Chum; Akash Goyal; Patrick Ruz; Katarzyna Mikrut; Orlando Simonetti; Hardeep Dholiya; Brijesh Patel; Daniel Addison
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

2.  Gateway and journey of patients with cardiac amyloidosis.

Authors:  Daniel Dang; Pauline Fournier; Eve Cariou; Antoine Huart; David Ribes; Pascal Cintas; Murielle Roussel; Magali Colombat; Yoan Lavie-Badie; Didier Carrié; Michel Galinier; Olivier Lairez
Journal:  ESC Heart Fail       Date:  2020-06-26

3.  Diagnostic Role of NT-proBNP in Patients with Cardiac Amyloidosis Involvement: A Meta-Analysis.

Authors:  Yingwei Zhang; Hasi Chaolu
Journal:  Arq Bras Cardiol       Date:  2022-08       Impact factor: 2.667

4.  3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis.

Authors:  Yumeng Liu; Jingfen Zhu; Meng Chen; Lingjie Wang; Mo Zhu; Zhen Weng; Chunhong Hu
Journal:  Ann Transl Med       Date:  2022-07

5.  Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study.

Authors:  Asan Agibetov; Benjamin Seirer; Theresa-Marie Dachs; Matthias Koschutnik; Daniel Dalos; René Rettl; Franz Duca; Lore Schrutka; Hermine Agis; Renate Kain; Michela Auer-Grumbach; Christina Binder; Julia Mascherbauer; Christian Hengstenberg; Matthias Samwald; Georg Dorffner; Diana Bonderman
Journal:  J Clin Med       Date:  2020-05-03       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.